Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.verified

KYMR

Price:

$43.07

Market Cap:

$2.64B

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fi...[Read more]

Industry

Biotechnology

IPO Date

2020-08-21

Stock Exchange

NASDAQ

Ticker

KYMR

The PE Ratio as of July 2024 (TTM) for Kymera Therapeutics, Inc. (KYMR) is -17.16

According to Kymera Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -17.16. This represents a change of 30.08% compared to the average of -13.19 of the last 4 quarters.

Kymera Therapeutics, Inc. (KYMR) Historical PE Ratio (quarterly & annually)

How has KYMR PE Ratio performed in the past?

The mean historical PE Ratio of Kymera Therapeutics, Inc. over the last ten years is -23.60. The current -17.16 PE Ratio has changed 7.17% with respect to the historical average. Over the past ten years (40 quarters), KYMR's PE Ratio was at its highest in in the September 2023 quarter at -3.84. The PE Ratio was at its lowest in in the December 2020 quarter at -54.34.

Quarterly (TTM)
Annual

Average

-23.60

Median

-27.78

Minimum

-35.87

Maximum

-8.87

Kymera Therapeutics, Inc. (KYMR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kymera Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 27.02%

Maximum Annual PE Ratio = -8.87

Minimum Annual Increase = -71.48%

Minimum Annual PE Ratio = -35.87

Quarterly (TTM)
Annual
YearPE RatioChange
2023-10.1114.04%
2022-8.87-71.48%
2021-31.0927.02%
2020-24.48-31.76%
2019-35.8714.95%

Kymera Therapeutics, Inc. (KYMR) Average PE Ratio

How has KYMR PE Ratio performed in the past?

The current PE Ratio of Kymera Therapeutics, Inc. (KYMR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-16.69

5-year avg

-22.08

10-year avg

-23.60

Kymera Therapeutics, Inc. (KYMR) PE Ratio vs. Peers

How is KYMR’s PE Ratio compared to its peers?

Kymera Therapeutics, Inc.’s PE Ratio is less than Foghorn Therapeutics Inc. (-2.90), less than Shattuck Labs, Inc. (-2.59), less than Monte Rosa Therapeutics, Inc. (-1.97), less than Nurix Therapeutics, Inc. (-8.01), less than Revolution Medicines, Inc. (-15.89), less than C4 Therapeutics, Inc. (-3.19), less than Agios Pharmaceuticals, Inc. (-7.77), less than Century Therapeutics, Inc. (-1.11), greater than Edgewise Therapeutics, Inc. (-17.53), less than Mineralys Therapeutics, Inc. (-6.78), less than Cullinan Oncology, Inc. (-6.67), less than Eliem Therapeutics, Inc. (-16.17), less than Prelude Therapeutics Incorporated (-3.57),

Build a custom stock screener for Kymera Therapeutics, Inc. (KYMR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kymera Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kymera Therapeutics, Inc. (KYMR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kymera Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Kymera Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Kymera Therapeutics, Inc. (KYMR)?

What is the highest PE Ratio for Kymera Therapeutics, Inc. (KYMR)?

What is the 3-year average PE Ratio for Kymera Therapeutics, Inc. (KYMR)?

What is the 5-year average PE Ratio for Kymera Therapeutics, Inc. (KYMR)?

How does the current PE Ratio for Kymera Therapeutics, Inc. (KYMR) compare to its historical average?